These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16524323)

  • 41. Assessing predictors of drug-induced torsade de pointes.
    Belardinelli L; Antzelevitch C; Vos MA
    Trends Pharmacol Sci; 2003 Dec; 24(12):619-25. PubMed ID: 14654302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug induced QT prolongation and torsades de pointes.
    Yap YG; Camm AJ
    Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906
    [No Abstract]   [Full Text] [Related]  

  • 43. Towards automation of a valuable preclinical cardiac safety pharmacology assay: Evaluation of the effects of cardiac ion channel blockers on cardiac repolarisation in vitro.
    Lightbown ID; Johnson M; Davis A; Leaney J; Leishman DJ
    J Pharmacol Toxicol Methods; 2007; 56(2):194-202. PubMed ID: 17583537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.
    Kågström J; Sjögren EL; Ericson AC
    J Pharmacol Toxicol Methods; 2007; 56(2):186-93. PubMed ID: 17582787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of nortriptyline on QT prolongation: a safety pharmacology study.
    Jeon SH; Jaekal J; Lee SH; Choi BH; Kim KS; Jeong HS; Han SY; Kim EJ
    Hum Exp Toxicol; 2011 Oct; 30(10):1649-56. PubMed ID: 21262863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Torsade de pointes: a new way to kill drugs].
    Tamargo Menéndez LJ
    An R Acad Nac Med (Madr); 1998; 115(1):23-42; discussion 42-6. PubMed ID: 9741134
    [No Abstract]   [Full Text] [Related]  

  • 48. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L; Breschi MC; Martinotti E; Calderone V
    J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Long QT-syndrome as a drug-induced side effect].
    Pohjola-Sintonen S
    Duodecim; 1998; 114(19):1891, 1893, 1895. PubMed ID: 11717743
    [No Abstract]   [Full Text] [Related]  

  • 50. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability.
    Hondeghem LM; Hoffmann P
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):14-24. PubMed ID: 12500017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.
    Orth PM; Hesketh JC; Mak CK; Yang Y; Lin S; Beatch GN; Ezrin AM; Fedida D
    Cardiovasc Res; 2006 Jun; 70(3):486-96. PubMed ID: 16545351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Torsades de pointes induced by nonantiarrhythmic drugs.
    Tran HT
    Conn Med; 1994 May; 58(5):291-5. PubMed ID: 7915666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long QT syndrome caused by noncardiac drugs.
    Viskin S; Justo D; Halkin A; Zeltser D
    Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
    Thomsen MB; Matz J; Volders PG; Vos MA
    Pharmacol Ther; 2006 Oct; 112(1):150-70. PubMed ID: 16714061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.